Cardiol Therapeutics Inc Class A (CRDL.TO) is experiencing a notable decline, closing down 3.42% in the latest trading session.
In this trading session, Cardiol Therapeutics Inc Class A saw its stock price drop to CA$1.41, reflecting a 3.42% decrease. This decline marks a tough day for investors, especially considering the company's recent operational updates and financing activities.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Cardiol Therapeutics Inc Class A
CRDL.TO
CRDL.TO
Cardiol Therapeutics Inc Class A
WealthAwesomeMarket cap
$192.50M
52W high
$2.33
52W low
$1.23
1W change
-6.29%
Beta
0.51
Analyst Price Targets
Based on analyst covering CRDL
Wall Street analysts forecast CRDL stock price to rise 265.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+265.9% Upside
Current Price
C$1.64
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRDL's historical volatility
30-Day Vol
50.9%
Annualized
90-Day Vol
60.2%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$1.37
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.55 | C$1.30 – C$1.84 |
| 60 trading days | C$1.46 | C$1.14 – C$1.87 |
| 90 trading days | C$1.37 | C$1.01 – C$1.86 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Keep an eye on Cardiol Therapeutics, as today's drop may indicate underlying concerns despite recent operational milestones.
CRDL.TO closes at CA$1.41, down 3.42%
With a market cap of CA$169.45 million, Cardiol Therapeutics' stock performance today shows investor caution amid ongoing operational developments.
Bull case
Despite the recent downturn, Cardiol Therapeutics has made significant strides, including progress in its clinical trials. These advancements could lead to long-term growth potential.
Bear case
The stock's decline today raises questions about market confidence in Cardiol's ongoing projects and financial health, particularly since there hasn't been any major news to support its current valuation.
Market Reaction
The 3.42% drop in Cardiol Therapeutics' stock price reflects a broader cautious sentiment among investors regarding the company's financial health. With a market cap around CA$169.45 million, this decline may suggest a lack of confidence in the recent operational updates and their impact on future growth.
Recent Developments
Cardiol Therapeutics has recently gained attention with important operational milestones, including the start of the Phase III MAVERIC trial and reaching a key patient enrollment milestone. However, the lack of immediate news to back today’s stock performance may have left investors uncertain about the company's future. For more details on these developments, check out our coverage on Cardiol's recent achievements.
Looking Ahead
As Cardiol Therapeutics navigates its clinical trials and operational challenges, investors should closely watch for upcoming announcements and market reactions. Understanding the potential risks and rewards in light of today’s performance will be crucial for making informed investment decisions. For more insights, visit our page on CRDL.TO.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
